Jpmorgan Chase & CO Theseus Pharmaceuticals, Inc. Transaction History

Jpmorgan Chase & CO

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	BUY	$2.12 - $4.18 $1,931 - $3,807	911 Added 6.93%	14,052 $56,000
Q3 2023 Nov 14, 2023	SELL	$2.66 - $10.04 $6,841 - $25,822	-2,572 Reduced 16.37%	13,141 $35,000
Q2 2023 Aug 11, 2023	BUY	$7.28 - $11.82 $19,481 - $31,630	2,676 Added 20.53%	15,713 $146,000
Q1 2023 May 18, 2023	BUY	$5.21 - $14.05 $67,813 - $182,874	13,016 Added 61980.95%	13,037 $115,000
Q1 2023 May 11, 2023	SELL	$5.21 - $14.05 $50,109 - $135,132	-9,618 Reduced 99.78%	21 $0
Q4 2022 Feb 13, 2023	BUY	$4.69 - $8.36 $2,251 - $4,012	480 Added 5.24%	9,639 $48,000
Q3 2022 Nov 14, 2022	BUY	$5.7 - $8.68 $427 - $651	75 Added 0.83%	9,159 $53,000
Q2 2022 Aug 11, 2022	BUY	$5.04 - $14.05 $18,582 - $51,802	3,687 Added 68.32%	9,084 $50,000
Q1 2022 May 11, 2022	BUY	$8.75 - $14.51 $2,528 - $4,193	289 Added 5.66%	5,397 $62,000
Q4 2021 Feb 10, 2022	BUY	$8.98 - $20.09 $45,869 - $102,619	5,108 New	5,108 $65,000

1.03M

Ticker THRX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 38,713,400
Description
Theseus Pharmaceuticals, Inc., a biopharmaceutical company, engages in the discovery, development, and commercialization of targeted therapies for the treatment of cancer patients. Its lead product candidate is THE-630, a pan-KIT inhibitor for the treatment of gastrointestinal stromal tumors, which is in Phase I clinical trial. The company also ...

Get notified when there are updates to the investment portfolio of Jpmorgan Chase & CO, based on Form 13F filings with the SEC.

Stay updated on Jpmorgan Chase & CO with notifications on news.